A Computerized Program (Neuroplasticity-Based Cognitive Remediation) for the Treatment of Chemotherapy Related Cognitive Impairment in Patients with Breast, Colon, Lymphoma, Endometrial, or Ovarian Cancer

Inclusion Criteria

• Have been diagnosed with noninvasive or invasive (stage 1, 2, or 3A) breast cancer, colon cancer, lymphoma, endometrial cancer or ovarian cancer
• Have undergone treatment with systemic chemotherapy within the last 1-8 years
• Endorse persistent chemotherapy-related cognitive impairment (CRCI) subjective complaints
• Have no active cardiac, neurologic, or psychiatric illness
• Fluent in and able to read English

Exclusion Criteria

• Any active neurologic psychiatric disease, clinically significant cognitive impairment or dementia, history of significant head trauma followed by persistent neurologic deficits, or known structural brain abnormalities
• Current major depression or another major psychiatric disorder as described in Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (use of central nervous system [CNS] active medications [e.g. antidepressants] will be permitted, provided dosing has been stable for at least 3 months)
• Any history of alcohol or substance abuse or dependence within the past 2 years (DSM-5 criteria)
• Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol
• Use of any investigational drugs within 30 days or 5 half-lives, whichever is longer, prior to screening
• Use of cholinergic agents will be discouraged but will be reviewed on a case-by-case basis by the principal investigator (PI)
• Red-green color blindness. Other types of color blindness will be reviewed on a case-by-case basis by the PI